Concepedia

Author

Michael Schmohl

Boehringer Ingelheim (Germany)

Also Known As

M. Schmohl, Michael Schmohl, Schmohl, Michael

27

Publications

995

Citations

12

H-Index

25

Concepts

All Affiliations

Boehringer Ingelheim (Germany)Boehringer Ingelheim (United States)Natural and Medical Sciences InstituteUniversity of TübingenBoehringer Ingelheim (Belgium)
MS

About

Michael Schmohl is an author at Boehringer Ingelheim (Germany) specializing in medicine, pharmacology, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

673

2

Immunology

2

2

260

3

Medical Laboratory Science

2

2

48

4

Public Health

1

1

33

5

Epidemiology

1

1

33

Michael Schmohl

×

12

Publications

917

Citations

11

H-Index

YearCitations

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial

Stephan Glund, Joachim Stangier, Michael Schmohl,

The Lancet

2015

317

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran

Viktoria Moschetti, Stephen H. Norris, Joachim Stangier,

Thrombosis and Haemostasis

2015

244

Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study

Stephan Glund, Joachim Stangier, Joanne van Ryn,

Clinical Pharmacokinetics

2016

85

Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects

Stephan Glund, Joachim Stangier, Michael Schmohl,

Blood

2014

70

Abstract 17765: A Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Healthy Male Volunteers

Stephan Glund, Joachim Stangier, Michael Schmohl,

Circulation

2013

48

Superficial Wound Swabbing

Michael Schmohl, Stefan Beckert, Thomas Joos,

Diabetes Care

2012

39

Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers

Michael Schmohl, Stephan Glund, Akiko Harada,

Thrombosis and Haemostasis

2016

33

Immune Profiling in Blood Identifies sTNF-R1 Performing Comparably Well as Biomarker Panels for Classification of Alzheimer's Disease Patients

Christoph Laske, Michael Schmohl, Thomas Leyhe,

Journal of Alzheimer s Disease

2013

22

Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study

Masahiro Yasaka, Ippei Ikushima, Akiko Harada,

Research and Practice in Thrombosis and Haemostasis

2017

17

Characterization of immunologically active drugs in a novel organotypic co-culture model of the human gut and whole blood

Michael Schmohl, Nicole Schneiderhan‐Marra, Nadja Baur,

International Immunopharmacology

2012

16

Page 1